H.C. Wainwright raised the firm’s price target on Tarsus Pharmaceuticals to $50 from $42 and keeps a Buy rating on the shares post the Q3 report. The analyst increased Xdemvy estimates and says Tarsus is capitalized through breakeven with the pipeline as upside.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on TARS:
- Tarsus Pharmaceuticals files $300M mixed securities shelf
- Tarsus Pharmaceuticals reports Q3 EPS ($1.28), consensus ($1.40)
- Tarsus Reports Third Quarter 2023 Financial Results and Recent Business Achievements
- Tarsus to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023
- Tarsus Pharmaceuticals price target raised to $49 from $46 at Guggenheim